Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Weinshenker

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|February 23, 2016
Pediatric familial neuromyelitis optica in two sisters with long term follow-upMiguel Chuquilin, Naresh Mullaguri, Brian Weinshenker
Neurologic Clinics|January 31, 2012
Acute demyelinating disorders: emergencies and managementReem F Bunyan, Junger Tang, Brian Weinshenker
Neurology|November 24, 2004
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled studyHillel Panitch, Aaron Miller, Donald Paty, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 13, 2020
Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteriaAndrew J Solomon, Roman Pettigrew, Robert T Naismith, et al.
Multiple Sclerosis and Related Disorders|October 7, 2019
Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from SerbiaJelena Drulovic, Vanja Martinovic, Irena Dujmovic Basuroski, et al.
Journal of the Neurological Sciences|September 20, 2005
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trialHillel Panitch, Douglas Goodin, Gordon Francis, et al.
Mayo Clinic Proceedings|December 11, 2021
CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple SclerosisRuba S Saadeh, Sandra C Bryant, Andrew McKeon, et al.
Multiple Sclerosis and Related Disorders|August 25, 2022
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStarTakashi Yamamura, Brian Weinshenker, Michael R Yeaman, et al.
Lancet (London, England)|August 16, 2005
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchangeMark Keegan, Fatima König, Robyn McClelland, et al.
Brain : a Journal of Neurology|June 22, 2002
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis opticaClaudia F Lucchinetti, Raul N Mandler, Dorian McGavern, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|February 23, 2016
Pediatric familial neuromyelitis optica in two sisters with long term follow-upMiguel Chuquilin, Naresh Mullaguri, Brian Weinshenker
Neurologic Clinics|January 31, 2012
Acute demyelinating disorders: emergencies and managementReem F Bunyan, Junger Tang, Brian Weinshenker
Neurology|November 24, 2004
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled studyHillel Panitch, Aaron Miller, Donald Paty, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 13, 2020
Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteriaAndrew J Solomon, Roman Pettigrew, Robert T Naismith, et al.
Multiple Sclerosis and Related Disorders|October 7, 2019
Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from SerbiaJelena Drulovic, Vanja Martinovic, Irena Dujmovic Basuroski, et al.
Journal of the Neurological Sciences|September 20, 2005
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trialHillel Panitch, Douglas Goodin, Gordon Francis, et al.
Mayo Clinic Proceedings|December 11, 2021
CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple SclerosisRuba S Saadeh, Sandra C Bryant, Andrew McKeon, et al.
Multiple Sclerosis and Related Disorders|August 25, 2022
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStarTakashi Yamamura, Brian Weinshenker, Michael R Yeaman, et al.
Lancet (London, England)|August 16, 2005
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchangeMark Keegan, Fatima König, Robyn McClelland, et al.
Brain : a Journal of Neurology|June 22, 2002
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis opticaClaudia F Lucchinetti, Raul N Mandler, Dorian McGavern, et al.
Pageof 3